Recursion Pharmaceuticals, Inc.

Item 2.02. Results of Operations and Financial Condition. On November 2, 2026, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2026, the Board of Directors (the “Board”) of the Company, upon the recommendation from its Nominating and Corporate Governance Committee (the “Nominating Committee”), increased the number of members of the Board from 9 to 10 and appointed Fred Hassan as Chair of the Board, effective immediately. The Board appointed Mr. Hassan as a Class II Director of the Board, with his initial term to extend until the 2029 Annual Meeting of Stockholders. Mr. Hassan has not yet been appointed to any committee of the Board. As a non-employee director, Mr. Hassan will receive cash and equity compensation paid by the Company pursuant to the Recursion Pharmaceuticals, Inc. Outside Director Compensation Policy (the “Director Compensation Policy”), which is described under the caption “Director Compensation - 2026 Changes to the Outside Director Compensation Policy” in the Company’s definitive proxy statement on Schedule 14A filed with the SEC on April 30, 2026, as amended by the Board from time to time, and Mr. Hassan will enter into an indemnification agreement with the Company on the Company’s standard form of indemnification agreement for officers and directors. There are no transactions in which Mr. Hassan has a direct or indirect material interest requiring disclosure under Item 404(a) of Regulation S-K and there are no arrangements or understandings between Mr. Hassan and any other person pursuant to which he was selected as a director of the Company.

Item 7.01. Regulation FD Disclosure. On November 2, 2026, the Company released a press release announcing the appointment of Mr. Hassan as Chair of the Board, as described in Item 5.02, above. A copy of the press release is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Also on November 2, 2026, the Company released a press release announcing the data presented at CGA-IGC conference on November 2, 2026. A copy of the press release is attached hereto as Exhibit 99.3 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. Also on November 2, 2026, the Company released a presentation made in connection with its earnings call on November 3, 2026. A copy of the presentation is attached hereto as Exhibit 99.4 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference. The information furnished pursuant to Item 2.02 (including Exhibit 99.1) and 7.01 (including Exhibits 99.2 and 99.3) on this Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.